# EDGAR Filing Document

**Accession Number:** 0001740279
**File Stem:** 0001714576-25-000003
**Filing Date:** 2025-12
**Character Count:** 62340
**Document Hash:** ecc410dfaa03f1ef9f0287520308d124
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001714576-25-000003.hdr.sgml**: 20251229

**ACCESSION NUMBER**: 0001714576-25-000003

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251229

**DATE AS OF CHANGE**: 20251229

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IN8BIO, INC.
- **CENTRAL INDEX KEY:** 0001740279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825462585
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92777
- **FILM NUMBER:** 251609047

**BUSINESS ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118
- **BUSINESS PHONE:** (646) 600-6438

**MAIL ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Incysus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20180510
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOS Fund II, LP
- **CENTRAL INDEX KEY:** 0001714576

**ORGANIZATION NAME:**
- **EIN:** 822436048
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1401 FOCH STREET
- **STREET 2:** SUITE 140
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76107
- **BUSINESS PHONE:** 817-984-5964

**MAIL ADDRESS:**
- **STREET 1:** 1401 FOCH STREET
- **STREET 2:** SUITE 140
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76107

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**IN8BIO, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**45674E109**

*(CUSIP Number)*

**Bios Equity Partners, LP**<br>1751 River Run<br>Suite 400<br>Fort Worth TX 76107<br>(817) 984-9197

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/22/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Fund II, LP** | Name of reporting person<br>**BIOS Fund II, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**19147.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**19147.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**19147.00** | Aggregate amount beneficially owned by each reporting person<br>**19147.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.2%** | Percent of class represented by amount in Row (11)<br>**0.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425  outstanding shares as of December 19, 2025, provided by Issuer.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Fund II QP, LP** | Name of reporting person<br>**BIOS Fund II QP, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**62554.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**62554.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**62554.00** | Aggregate amount beneficially owned by each reporting person<br>**62554.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.6%** | Percent of class represented by amount in Row (11)<br>**0.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Fund II NT, LP** | Name of reporting person<br>**BIOS Fund II NT, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8373.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8373.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8373.00** | Aggregate amount beneficially owned by each reporting person<br>**8373.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.1%** | Percent of class represented by amount in Row (11)<br>**0.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Incysus Co-Invest I, LP** | Name of reporting person<br>**BIOS Incysus Co-Invest I, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**33247.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**33247.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**33247.00** | Aggregate amount beneficially owned by each reporting person<br>**33247.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.3%** | Percent of class represented by amount in Row (11)<br>**0.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer. As of December 24, 2025, all shares owned by BIOS Incysus Co-Invest I, LP have been sold.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Fund III, LP** | Name of reporting person<br>**BIOS Fund III, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**19024.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**19024.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**19024.00** | Aggregate amount beneficially owned by each reporting person<br>**19024.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.2%** | Percent of class represented by amount in Row (11)<br>**0.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Fund III QP, LP** | Name of reporting person<br>**BIOS Fund III QP, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**124253.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**124253.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**124253.00** | Aggregate amount beneficially owned by each reporting person<br>**124253.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.3%** | Percent of class represented by amount in Row (11)<br>**1.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Fund III NT, LP** | Name of reporting person<br>**BIOS Fund III NT, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**20066.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**20066.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**20066.00** | Aggregate amount beneficially owned by each reporting person<br>**20066.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.2%** | Percent of class represented by amount in Row (11)<br>**0.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Bios Clinical Opportunity Fund, LP** | Name of reporting person<br>**Bios Clinical Opportunity Fund, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**104693.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**104693.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**104693.00** | Aggregate amount beneficially owned by each reporting person<br>**104693.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.1%** | Percent of class represented by amount in Row (11)<br>**1.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power includes a total of 104,693 shares of common stock, par value $0.0001 per share ("Shares") issuable upon the exercise of warrants directly held by Bios Clinical Opportunity Fund, LP ("Bios COF"), consisting of 81,059 pre-funded warrants and 23,634 Series C warrants as of the date hereof (together, the "Bios COF Warrants"). All of the Bios COF Warrants are exercisable as of the date hereof. However, each of the Bios COF Warrants is subject to a restriction on exercise to the extent the beneficial ownership of the Reporting Persons would exceed 9.99% (the "Beneficial Ownership Limitation").

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BP Directors, LP** | Name of reporting person<br>**BP Directors, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of 0 Shares issuable upon exercise of options granted in consideration for Travis Whitfill's services as a director of the Issuer, which are exercisable or will be immediately exercisable within 60 days of the date hereof (the "Bios Directors Options"). Pursuant to an agreement with BP Directors, LP ("Bios Directors"), Mr. Whitfill has agreed that he will hold certain equity-based awards granted to him in connection with his services as a director of the Issuer while affiliated with Bios Directors (including the Bios Directors Options) merely as a nominee for Bios Directors. Mr. Whitfill is not currently an affiliate of any of the Reporting Persons. Percentage based on 9,761,425 Shares, consisting of (i) 9,761,425 Shares outstanding as of December 19, 2025, provided by Issuer, and (ii) 0 Shares issuable upon exercise of the Bios Directors Options.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Bios Equity Partners, LP** | Name of reporting person<br>**Bios Equity Partners, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.0%** | Percent of class represented by amount in Row (11)<br>**0.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer.

Shared voting and dispositive power consists of 0 Shares issuable upon exercise of the Bios Directors Options. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Directors. In its capacity as the general partner of Bios Directors, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Bios Equity Partners II, LP** | Name of reporting person<br>**Bios Equity Partners II, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**123321.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**123321.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**123321.00** | Aggregate amount beneficially owned by each reporting person<br>**123321.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.3%** | Percent of class represented by amount in Row (11)<br>**1.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer.

Shared voting and dispositive power consists of of (i) 19,147 Shares directly held by Bios Fund II, LP ("Bios Fund II"), (ii) 62,554 Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP"), (iii) 8,373 Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT") and (iv) 33,247 Shares directly held by BIOS Incysus Co-Invest I, LP ("BIOS Incysus"), in each case, as of the date hereof. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP, Bios Fund II NT and BIOS Incysus. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Equity Partners III, LP** | Name of reporting person<br>**BIOS Equity Partners III, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**163343.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**163343.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**163343.00** | Aggregate amount beneficially owned by each reporting person<br>**163343.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.7%** | Percent of class represented by amount in Row (11)<br>**1.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage based on 9,761,425 outstanding shares as of December 19, 2025, provided by Issuer.

Shared voting and dispositive power consists of of (i) 19,024 Shares directly held by Bios Fund III, LP ("Bios Fund III"), (ii) 124,253 Shares directly held by Bios Fund III QP ("Bios Fund III QP"), and (iii) 20,066 Shares directly held by Bios Fund III NT ("Bios Fund III NT"), in each case, as of the date hereof. Bios Equity Partners III, LP ("Bios Equity III") is the general partner of Bios Fund III, Bios Fund III QP and Bios Fund III NT. In its capacity as the general partner of these entities, Bios Equity III may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Bios Equity COF, LP** | Name of reporting person<br>**Bios Equity COF, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**104693.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**104693.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**104693.00** | Aggregate amount beneficially owned by each reporting person<br>**104693.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.1%** | Percent of class represented by amount in Row (11)<br>**1.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power includes a total of 104,693 Shares issuable upon the exercise of the Bios COF Warrants that are not currently exercisable due to the Beneficial Ownership Limitation. Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios COF. In its capacity as the general partner of Bios COF, Bios Equity COF may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios COF.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Cavu Management, LP** | Name of reporting person<br>**Cavu Management, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**286664.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**286664.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**286664.00** | Aggregate amount beneficially owned by each reporting person<br>**286664.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.9%** | Percent of class represented by amount in Row (11)<br>**2.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 0 Shares issuable upon exercise of the Bios Directors Options, (ii) 19,147 Shares directly held by Bios Fund II, (iii) 62,554 Shares directly held by Bios Fund II QP, (iv) 8,373 Shares directly held by Bios Fund II NT, (v) 33,247 Shares directly held by BIOS Incysus, (vi) ) 19,024 Shares directly held by Bios Fund III, (vii) 124,253 Shares directly held by Bios Fund III QP and (viii) 20,066 Shares directly held by Bios Fund III NT, in each case, as of the date hereof. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively the "Bios Equity II Entities"). Bios Equity Partners III is the general partner of Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively the "Bios Equity III Entities"). Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I, Bios Equity II and Bios Equity III. In its capacity as a general partner of Bios Equity I, Bios Equity II and Bios Equity III, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities and the Bios Equity III Entities. Percentage based on 9,761,425 Shares, consisting of (i) 9,761,425 Shares outstanding as of December 19, 2025, provided by Issuer, and (ii) 0 Shares issuable upon exercise of the Bios Directors Options.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Capital Management, LP** | Name of reporting person<br>**BIOS Capital Management, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**391357.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**391357.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**391357.00** | Aggregate amount beneficially owned by each reporting person<br>**391357.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.0%** | Percent of class represented by amount in Row (11)<br>**4.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 0 Shares issuable upon exercise of the Bios Directors Options, (ii) 19,147 Shares directly held by Bios Fund II, (iii) 62,554 Shares directly held by Bios Fund II QP, (iv) 8,373 Shares directly held by Bios Fund II NT, (v) 33,247 Shares directly held by BIOS Incysus, (vi) ) 19,024 Shares directly held by Bios Fund III, (vii) 124,253 Shares directly held by Bios Fund III QP, (viii) 20,066 Shares directly held by Bios Fund III NT, and (ix) 104,693 Shares issuable upon exercise of the Bios COF Warrants, in each case, as of the date hereof. Excludes a total of 2,742,506 Shares issuable upon the exercise of the Bios COF Warrants that are not currently exercisable due to the Beneficial Ownership Limitation. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner of the Bios III Entities. Bios Equity COF is the general partner of Bios COF. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I, Bios Equity II, Bios Equity III, and is the general partner of Bios Equity COF. In its capacity as a general partner of Bios Equity I, Bios Equity II and Bios Equity III and the general partner of Bios Equity COF, Bios Management may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities, the Bios Equity III Entities and Bios COF. Percentage based on 9,866,118 Shares, consisting of (i) 9,761,425 Shares outstanding as of December 19, 2025, provided by Issuer, (ii) 0 Shares issuable upon exercise of the Bios Directors Options, and (iii) 104,693 Shares issuable upon exercise of the Bios COF Warrants.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Cavu Advisors, LLC** | Name of reporting person<br>**Cavu Advisors, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**286664.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**286664.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**286664.00** | Aggregate amount beneficially owned by each reporting person<br>**286664.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.9%** | Percent of class represented by amount in Row (11)<br>**2.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 0 Shares issuable upon exercise of the Bios Directors Options, (ii) 19,147 Shares directly held by Bios Fund II, (iii) 62,554 Shares directly held by Bios Fund II QP, (iv) 8,373 Shares directly held by Bios Fund II NT, (v) 33,247 Shares directly held by BIOS Incysus, (vi) ) 19,024 Shares directly held by Bios Fund III, (vii) 124,253 Shares directly held by Bios Fund III QP and (viii) 20,066 Shares directly held by Bios Fund III NT, in each case, as of the date hereof. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively the "Bios Equity II Entities"). Bios Equity Partners III is the general partner of Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively the "Bios Equity III Entities"). Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I, Bios Equity II and Bios Equity III. In its capacity as a general partner of Bios Equity I, Bios Equity II and Bios Equity III, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities and the Bios Equity III Entities. Percentage based on 9,761,425 Shares, consisting of (i) 9,761,425 Shares outstanding as of December 19, 2025, provided by Issuer, and (ii) 0 Shares issuable upon exercise of the Bios Directors Options.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS Advisors GP, LLC** | Name of reporting person<br>**BIOS Advisors GP, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**391357.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**391357.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**391357.00** | Aggregate amount beneficially owned by each reporting person<br>**391357.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.0%** | Percent of class represented by amount in Row (11)<br>**4.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 0 Shares issuable upon exercise of the Bios Directors Options, (ii) 19,147 Shares directly held by Bios Fund II, (iii) 62,554 Shares directly held by Bios Fund II QP, (iv) 8,373 Shares directly held by Bios Fund II NT, (v) 33,247 Shares directly held by BIOS Incysus, (vi) 19,024 Shares directly held by Bios Fund III, (vii) 124,253 Shares directly held by Bios Fund III QP (viii) 20,066 Shares directly held by Bios Fund III NT, and (ix) 104,693 Shares issuable upon exercise of the Bios COF Warrants, in each case, as of the date hereof. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner of the Bios III Entities. Bios Equity COF is the general partner of Bios COF. Bios Management is a general partner of Bios Equity I, Bios Equity II and Bios Equity III, and is the general partner of Bios Equity COF. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities, the Bios Equity III Entities and Bios COF. Percentage based on 9,866,118 Shares, consisting of (i) 9,761,425 Shares outstanding as of December 19, 2025, provided by Issuer, (ii) 0 Shares issuable upon exercise of the Bios Directors Options, and (iii) 104,693 Shares issuable upon exercise of the Bios COF Warrants.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Kreis Leslie W.** | Name of reporting person<br>**Kreis Leslie W.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**286664.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**286664.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**286664.00** | Aggregate amount beneficially owned by each reporting person<br>**286664.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.9%** | Percent of class represented by amount in Row (11)<br>**2.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 0 Shares issuable upon exercise of the Bios Directors Options, (ii) 19,147 Shares directly held by Bios Fund II, (iii) 62,554 Shares directly held by Bios Fund II QP, (iv) 8,373 Shares directly held by Bios Fund II NT, (v) 33,247 Shares directly held by BIOS Incysus, (vi) ) 19,024 Shares directly held by Bios Fund III, (vii) 124,253 Shares directly held by Bios Fund III QP and (viii) 20,066 Shares directly held by Bios Fund III NT, in each case, as of the date hereof. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner the Bios III Entities. Cavu Management, LP is a general partner of Bios Equity I, Bios Equity II, and Bios Equity III. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities and the Bios Equity III Entities. Percentage based on 9,761,425 Shares, consisting of (i) 9,761,425 Shares outstanding as of December 19, 2025, provided by Issuer, and (ii) 0 Shares issuable upon exercise of the Bios Directors Options.

| **CUSIP No.** | **45674E109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Fletcher Aaron G.L.** | Name of reporting person<br>**Fletcher Aaron G.L.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**391357.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**391357.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**391357.00** | Aggregate amount beneficially owned by each reporting person<br>**391357.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.0%** | Percent of class represented by amount in Row (11)<br>**4.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 0 Shares issuable upon exercise of the Bios Directors Options, (ii) 19,147 Shares directly held by Bios Fund II, (iii) 62,554 Shares directly held by Bios Fund II QP, (iv) 8,373 Shares directly held by Bios Fund II NT, (v) 33,247 Shares directly held by BIOS Incysus, (vi) ) 19,024 Shares directly held by Bios Fund III, (vii) 124,253 Shares directly held by Bios Fund III QP (viii) 20,066 Shares directly held by Bios Fund III NT, and (ix), 398,297 Shares issuable upon exercise of the Bios COF Warrants, in each case, as of the date hereof. Excludes a total of 2,742,506 Shares issuable upon the exercise of the Bios COF Warrants that are not currently exercisable due to the Beneficial Ownership Limitation. Bios Equity Partners I is the general partner of Bios Directors. Bios Equity Partners II is the general partner of the Bios II Entities. Bios Equity Partners III is the general partner of the Bios III Entities. Bios Equity COF is the general partner of Bios COF. Bios Management is a general partner of Bios Equity I, Bios Equity II and Bios Equity III, and is the general partner of Bios Equity COF. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by Bios Directors, the Bios Equity II Entities, the Bios Equity III Entities and Bios COF. Percentage based on 9,866,118 Shares, consisting of (i) 9,761,425 Shares outstanding as of December 19, 2025, provided by Issuer, (ii) 0 Shares issuable upon exercise of the Bios Directors Options and (iii) 104,693 Shares issuable upon exercise of Bios COF Warrants.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
IN8BIO, INC.

**(c) Address of Issuer's Principal Executive Offices:**
EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained on the cover pages of this Schedule 13D is incorporated herein by reference

**(b)**
The information contained on the cover pages of this Schedule 13D is incorporated herein by reference

**(c)**
Except as otherwise disclosed in Item 6 below, none of the Reporting Persons, nor, to the best of the Reporting Persons' knowledge, any of their respective executive officers or directors, as applicable, has acquired or disposed of, any securities of the Issuer during the 60 days prior to the date hereof.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between the Issuer and Bios COF, Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock (the "Series A Warrants"), (ii) 574,241 Series B Warrants to purchase one share of Common Stock (the "Series B Warrants") and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrants are exercised in full.; provided, however, that the exercise of such Pre-Funded Warrants is subject to a 9.99% beneficial ownership limitation.
The summary of the Warrant Exchange Agreement contained herein is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as an exhibit hereto.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Fund II, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Fund II QP, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Fund II NT, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Incysus Co-Invest I, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Fund III, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Fund III QP, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Fund III NT, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Bios Clinical Opportunity Fund, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BP Directors, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Bios Equity Partners, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Bios Equity Partners II, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Equity Partners III, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Bios Equity COF, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Cavu Management, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Capital Management, LP

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Cavu Advisors, LLC

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS Advisors GP, LLC

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci/Attorney-in-Fact

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Kreis Leslie W.

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr.

**Date:** 12/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Fletcher Aaron G.L.

**Signature:** /s/ John Fucci

**Name/Title:** John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher

**Date:** 12/24/2025